AMD discovery: New hope for treatment of vision loss

Scientists have won a major battle in the fight against age-related macular degeneration, or AMD, a blinding eye disease that affects millions of people. An international team, led by researchers at Sainte-Justine Hospital and the Université de Montréal, has identified the deficient receptor that causes the dry form of AMD.

In the February edition of the medical journal PLoS Medicine, the researchers explain how a deficiency of the CD36 receptor prevents the evacuation of oxidized lipids in the eye. Those oxidized lipids in turn accumulate and attack the layers beneath and over the retina – thereby causing vision loss.

“Our discovery has important implications for the development of new therapies,” explains lead researcher, Dr. Sylvain Chemtob, who co-authored the paper with Université de Montréal collaborator Dr. Huy Ong, a professor at the Faculty of Pharmacy, as well as Florian Sennlaub of the Institut national de la santé et de la recherche médicale (INSERM) in France.

Chemtob, a neonatal researcher at Sainte-Justine Hospital and a professor at the Université de Montréal’s Department of Pediatrics and School of Optometry, used mice and rat models to pinpoint the scavenger receptor responsible for retinal degeneration typical of dry AMD. “We found that a deficiency in CD36 receptors leads to significant and progressive age-related macular degeneration,” he says. “CD36 deficiency leads to central vision loss – a key feature of dry AMD.”

“This discovery brings us one step closer to treating dry AMD, which could significantly improve the quality of life of seniors who are most affected by this eye disease,” added co-author Dr. Huy Ong. “Now that we have also developed the molecules that activate CD 36 receptor, we are working on the validation of the efficacy of these molecules as potential therapeutic agents for dry AMD treatment with prospect at the horizon of 2015.”

Wet and dry AMD remain an alarming cause of vision loss in the western world, which according to the AMD Alliance International, affect 30 million people aged 50 and over. Dry AMD is the most pervasive of the disorders and affects 90 percent of AMD cases.

Source: University of Montreal

Related stories:

Retina transplants show promise in patients with retinal degeneration
Preliminary research shows encouraging results with transplantation of retinal cells in patients with blindness caused by retinitis pigmentosa (RP) and age-related macular degeneration (AMD), according to a report in the August issue of American Journal of Ophthalmology.
Physician revolutionizes gene research
A dramatic new study published in the most recent issue of Nature questions some of the mechanisms underlying a new class of drugs based on Nobel Prize-winning work designed to fight diseases ranging from macular degeneration to diabetes.
Study paves way for development of macular degeneration cures
A new study of age-related macular degeneration (AMD), a disease that affects more than nine million Americans, will pave the way for the biopharmaceutical industry to develop better treatments and cures, according to the Foundation Fighting Blindness, which partially funded the research.
Gene variant increases risk of blindness
Researchers have found a gene variant that can more than double the risk of developing the degenerative eye disease, age-related macular degeneration.
New angiogenesis finding may help fight cancer growth
A researcher at the University of Wisconsin-Madison School of Medicine and Public Health has discovered a new part of the complicated mechanism that governs the formation of blood vessels, or angiogenesis.
Europeans expand antitrust case against Intel
(AP) -- European Union regulators have expanded their antitrust case against Intel Corp., claiming that the world's largest semiconductor maker has deliberately squeezed rival AMD out of the chip market.
AMD changes CEO as turnaround pressure intensifies
(AP) -- Under Hector Ruiz's leadership, chip maker Advanced Micro Devices Inc. rose to challenge larger rival Intel Corp. as never before in AMD's nearly 40-year history.
AMD 2Q loss widens, worse than analyst forecast
(AP) -- Advanced Micro Devices Inc. said Thursday its second-quarter loss widened as the computer chip maker was hurt by a large asset impairment charge from discontinued operations.

News discussion:

Medicine & Health news